Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer

Journal of the American College of Cardiology

Volumn 60, Issue 24, 2012, Pages 2504-2512

  Chen, Jersey ^a   Long, Jessica B ^a   Hurria, Arti ^b   Owusu, Cynthia ^c   Steingart, Richard M ^d   Gross, Cary P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b City of Hope   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

anthracycline; cardiomyopathy; chemotherapy; epidemiology; heart failure; trastuzumab

Indexed keywords

ANTHRACYCLINE; TRASTUZUMAB;

ADJUVANT THERAPY; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CARDIOMYOPATHY; DEMOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; MORBIDITY; POISSON DISTRIBUTION; PRIORITY JOURNAL; SOCIAL ASPECT;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOMYOPATHIES; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; SEER PROGRAM;

EID: 84871319147     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.07.068     Document Type: Article

References (34)

1. E. Yeh, C.L. Bickford Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management J Am Coll Cardiol 53 2009 2231 2247
2. S. Swain, F. Whaley, M. Ewer Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials Cancer 97 2003 2869 2879
3. D.D. Von Hoff, M.W. Layard, P. Basa Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 1979 710 717
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
5. M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
6. E.H. Romond, E.A. Perez, J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684
7. D. Slamon, W. Eiermann, N. Robert Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 2011 1273 1283
8. E. Bria, F. Cuppone, M. Fornier Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials Breast Cancer Res Treat 109 2008 231 239
9. C. Serrano, J. Cortes, L. De Mattos-Arruda Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors Ann Oncol 23 2012 897 902
10. National Cancer Institute Cancer of the breast SEER stat fact sheet http://seer.cancer.gov/statfacts/html/breast.html Accessed February 22, 2012
11. D. Cardinale, A. Colombo, G. Lamantia Cardio-oncology: a new medical issue Ecancermedicalscience 2 2008 126
12. G.J. Yoon, M.L. Telli, D.P. Kao, K.Y. Matsuda, R.W. Carlson, R.M. Witteles Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies: are clinicians responding optimally? J Am Coll Cardiol 56 2010 1644 1650
13. J.L. Warren, C.N. Klabunde, D. Schrag, P.B. Bach, G.F. Riley Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population Med Care 40 2002 IV-3-18
14. A. Elixhauser, C. Steiner, D. Harris, R. Coffey Comorbidity measures for use with administrative data Med Care 36 1998 8 27
15. J.L. Warren, L.C. Harlan, A. Fahey Utility of the SEER-Medicare data to identify chemotherapy use Med Care 40 2002 IV-55-61
16. C.N. Klabunde, J.L. Warren, J.M. Legler Assessing comorbidity using claims data: an overview Med Care 40 2002 26 35 IV-26-35
17. B.A. Virnig, J.L. Warren, G.S. Cooper, C.N. Klabunde, N. Schussler, J. Freeman Studying radiation therapy using SEER-Medicare-linked data Med Care 40 2002 IV-49-54
18. L.M. Baldwin, C.N. Klabunde, P. Green, W. Barlow, G. Wright In search of the perfect comorbidity measure for use with administrative claims data: does it exist? Med Care 44 2006 745 753
19. C.M. Tammemagi, D. Nerenz, C. Neslund-Dudas, C. Feldkamp, D. Nathanson Comorbidity and survival disparities among black and white patients with breast cancer JAMA 294 2005 1765 1772
20. K.A. Wouters, L.C.M. Kremer, T.L. Miller, E.H. Herman, S.E. Lipshultz Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies Br J Haematol 131 2005 561 578
21. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology Breast Cancer. Version 1.2012 http://www.nccn.org Accessed June 29, 2012
22. X.L. Du, R. Xia, K. Burau, C.C. Liu Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005 Med Oncol 28 2011 S80 S90
23. G.A. Viani, S.L. Afonso, E.J. Stefano, L.I. De Fendi, F.V. Soares Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials BMC Cancer 7 2007 153
24. A. Albini, G. Pennesi, F. Donatelli, R. Cammarota, S.D. Flora, D.M. Noonan Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention J Natl Cancer Inst 102 2010 14 25
25. D.M. Lloyd-Jones, M.G. Larson, E.P. Leip Lifetime risk for developing congestive heart failure: the Framingham Heart Study Circulation 106 2002 3068 3072
26. D. Slamon, W. Eiermann, N. Robert Adjuvant trastuzumab in HER2-positive breast cancer Supplemental Material: Trial protocol http://www.nejm.org/doi/ suppl/10.1056/NEJMoa0910383/suppl-file/nejmoa0910383-appendix.pdf N Engl J Med 365 2011 1273 1283
27. D. Cardinale, A. Colombo, M.T. Sandri Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 114 2006 2474 2481
28. L.H. Curtis, D.J. Whellan, B.G. Hammill Incidence and prevalence of heart failure in elderly persons, 1994-2003 Arch Intern Med 168 2008 418 424
29. National Institutes of Health National Heart, Lung, and Blood Institute 2006 NHLBI Incidence and Prevalence Chartbook http://www.nhlbi.nih.gov/ resources/docs/cht-book-ip.htm Accessed July 9, 2012
30. E. Birman-Deych, A.D. Waterman, Y. Yan, D.S. Nilasena, M.J. Radford, B.F. Gage Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors Med Care 43 2005 480 485
31. D.C. Goff Jr., D.K. Pandey, F.A. Chan, C. Ortiz, M.Z. Nichaman Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi Heart Project Arch Intern Med 160 2000 197 202
32. D.S. Lee, L. Donovan, P.C. Austin Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research Med Care 43 2005 182 188
33. W.D. Rosamond, P.P. Chang, C. Baggett Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria Circ Heart Fail 5 2012 152 159
34. N. Kalay, E. Basar, I. Ozdogru Protective effects of carvedilol against anthracycline-induced cardiomyopathy J Am Coll Cardiol 48 2006 2258 2262